University of Missouri Homepage
Print    Email
Decrease (-) Restore Default Increase (+) font size
Cardiovascular Medicine - Active Clinical Trials

Clinical Trails Currently Enrolling
To refer a patient to any cardiovascular medicine trial, page the on-call pager number at (573) 499-8084.

 Trial  Investigators  Description
CANTOS Drs. Webel/Aggarwal/Kumar Canakinumab vs. Placebo in the prevention of recurrent cardiovascular events in Post-MI patients with elevated hsCRP 
EXACT-HF Drs. Flaker/Dohrmann Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients using Allopurinol vs. Placebo
PEGASUS--TIMI 54 Drs. Aggarwal/Kumar Ticagrelor vs. Placebo to assess the prevention of thrombotic events in patients 1-3 years post MI
RAID Drs. Flaker/Weachter Late Sodium Current Blockade in High-Risk ICD patients using Ranolazine vs. Placebo

Registry Trials - Currently Enrolling

Trial Investigators Description
ACTION Dr. Aggarwal Can rapid risk stratification of unstable angina patients suppress adverse outcomes with early implementation of the ACC/AHA Guidelines
Medtronic--PPP/AAF Drs. Weachter/Flaker Post-market surveillance to document product performance assessment of Medtronic device leads
Pre-Determine Dr. Flaker Observational prospective study to identify genetic markers & biomarkers that predict the risk of arrhythmic death among CAD patients with preserved left ventricular ejection fraction (LVEF >35%)

Ongoing Clinical Trials - Not Enrolling




AVERROES--LTOLE Drs. Weachter/Flaker Apixaban vs. Aspirin to prevent stroke in A-fib patients unsuitable for warfarin.  Long term open label extension
AQUARIUS Drs. Webel/Aggarwal/Kumar Aliskiren vs. Placebo to evaluate efficacy on the progression of atherosclerosis via coronary intravascular ultrasound 
IMPROVE-IT Drs. Aggarwal/Weachter/Flaker Vytorin vs. Simvastatin in High Risk subjects presenting with ACS 
REVEAL TIMI--55 Drs. Aggarwal/Webel  Does inhibition of cholesteryl ester transfer protein (Anacetrapib vs. Placebo) prevent major vascular events in patients with vascular disease?
SOLID TIMI--52 Drs. Aggarwal/Kumar/Senthilkumar Darapladib (Lp-PLA2 inhibitor) vs. placebo in acute coronary syndrome to compare the incidence of major cardiovascular adverse events 
 TRANSLATE--ACS Dr. Webel  Observational prospective study to assess treatment with ADP receptor inhibitors after hospitalization with an ACS event

Human Resources Giving Disclaimer Notice of Privacy Practices Web Communications Social Media Site Index
Mizzou University of Missouri University of Missouri System